Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments
PPAR Research · 31.08.2022 · 2022 · 1-43
DOI: 10.1155/2022/4714914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PPAR Research, erschienen am 31.08.2022. Verfasst von Ayesheh Enayati und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Peroxisome proliferator-activated receptors (PPARs) are members of the ligand-dependent nuclear receptor family. PPARs have attracted wide attention as pharmacologic mediators to manage multiple diseases and their underlying signaling targets. They mediate a broad range of specific biological activities and multiple organ toxicity, including cellular differentiation, metabolic syndrome, cancer, atherosclerosis, neurodegeneration, cardiovascular diseases, and inflammation related to their up/downstream signaling pathways. Consequently, several types of selective PPAR ligands, such as fibrates and thiazolidinediones (TZDs), have been approved as their pharmacological agonists. Despite these advances, the use of PPAR agonists is known to cause adverse effects in various systems. Conversely, some naturally occurring PPAR agonists, including polyunsaturated fatty acids and natural endogenous PPAR agonists curcumin and resveratrol, have been introduced as safe agonists as a result of their clinical evidence or preclinical experiments. This review focuses on research on plant-derived active ingredients (natural phytochemicals) as potential safe and promising PPAR agonists. Moreover, it provides a comprehensive review and critique of the role of phytochemicals in PPARs-related diseases and provides an understanding of phytochemical-mediated PPAR-dependent and -independent cascades. The findings of this research will help to define the functions of phytochemicals as potent PPAR pharmacological agonists in underlying disease mechanisms and their related complications.
Autor:innen und Institutionen
- Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
- Discipline of Pharmacology, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.
- NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia.
- Department of Pharmacology and Toxicology, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq.
- Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID-Profile: Amirhossein Sahebkar
Zitieren
APA
Enayati, A., Ghojoghnejad, M., Roufogalis, B. D., Maollem, S. A., & Sahebkar, A. (2022). Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments. PPAR Research, 2022, 1-43. https://doi.org/10.1155/2022/4714914
Vancouver
Enayati A, Ghojoghnejad M, Roufogalis BD, Maollem SA, Sahebkar A. Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments. PPAR Research. 2022;2022:1-43. doi:10.1155/2022/4714914
BibTeX
@article{Enayati2022,
author = {Enayati, Ayesheh and Ghojoghnejad, Mobina and Roufogalis, Basil D and Maollem, Seyed Adel and Sahebkar, Amirhossein},
title = {Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments},
journal = {PPAR Research},
year = {2022},
volume = {2022},
pages = {1--43},
doi = {10.1155/2022/4714914}
}
EUVIMED